<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0864-0289</journal-id>
<journal-title><![CDATA[Revista Cubana de Hematología, Inmunología y Hemoterapia]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Cubana Hematol Inmunol Hemoter]]></abbrev-journal-title>
<issn>0864-0289</issn>
<publisher>
<publisher-name><![CDATA[Centro Nacional de Información de Ciencias MédicasEditorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0864-02892020000200010</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Respuesta a la prueba de desmopresina: estudio de cohorte en un hospital de Bogotá]]></article-title>
<article-title xml:lang="en"><![CDATA[Response to the desmopressin test: cohort study in a Bogota hospital]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Solano-Trujillo]]></surname>
<given-names><![CDATA[María-Helena]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Casas-Patarroyo]]></surname>
<given-names><![CDATA[Claudia-Patricia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Espinosa-Redondo]]></surname>
<given-names><![CDATA[Daniel-Lorenzo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Abello-Polo]]></surname>
<given-names><![CDATA[Virginia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Parra]]></surname>
<given-names><![CDATA[Lucía]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Palacios]]></surname>
<given-names><![CDATA[Alejandro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital de San José  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2020</year>
</pub-date>
<volume>36</volume>
<numero>2</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S0864-02892020000200010&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S0864-02892020000200010&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S0864-02892020000200010&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  La desmopresina es un análogo sintético de la vasopresina que aumenta los niveles plasmáticos del factor VIII y del factor de von Willebrand. Algunos autores señalan el tiempo de mantenimiento del efecto hemostático entre 6 y 8 h, por lo que es necesario estudiar su efecto en el tiempo.  Objetivo:  Determinar la variación de las variables de laboratorio de pacientes con enfermedad de von Willebrand y hemofilia tipo A posterior a la administración de desmopresina.  Métodos:  Estudio de cohorte retrospectivo en un hospital universitario en Bogotá. Se realizó un muestreo no aleatorio, se incluyeron 24 pacientes mayores de 18 años con diagnóstico de enfermedad de von Willebrand (67 %) y hemofilia tipo A no grave (33 %), a quienes se les realizó la prueba de desmopresina. Se conformaron dos grupos de pacientes, independientemente del diagnóstico: 15 pacientes con valores basales de factor VIII &lt; 50 UI y 13 pacientes con valores basales de antígeno von Willebrand &lt; 50 UI. Se efectúo análisis estadístico descriptivo y correlacional en Stata 13.  Resultados:  El 87 % de los pacientes del grupo I alcanzó el valor terapéutico a las 2 h de administrada la desmopresina (p= 0,000), el cual se mantuvo hasta 6 h en el 77 % (p= 0,000). En el grupo II el 92 % logró el valor terapéutico en 2 h (p= 0,003), que continuó hasta las 6 h en el 83 % (p= 0,000).  Conclusiones:  La respuesta a la administración de desmopresina fue máxima a las 2 h posteriores, cuando comenzó a disminuir progresivamente, pero mantuvo el efecto terapéutico. Aunque no se encontraron efectos adversos, existe variabilidad de respuesta entre pacientes.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  Desmopressin is a synthetic analog for vasopressin that increases the plasma levels of factor VIII and of von Willebrand factor. Some authors indicate maintenance time of hemostatic effect between 6 and 8 hours, so it is necessary to study its effect over time.  Objective:  To determine the variation of laboratory variables in patients with von Willebrand disease and type A hemophilia after desmopressin administration.  Methods:  Retrospective cohort study carried out in a university hospital in Bogotá. Nonrandomized sampling was used, including 24 patients older than 18 years and with a diagnosis of von Willebrand disease (67%) and non-severe type A hemophilia (33%), who underwent the desmopressin test. Two groups of patients were created, regardless of diagnosis: 15 patients with baseline values of factor-VIII &#8203;&#8203;lower than 50 IU and 13 patients with baseline values of von Willebrand antigen &#8203;&#8203;lower than 50 IU. Descriptive and correlational statistical analysis was performed in Stata 13.  Results: 87% of patients in group I reached the therapeutic value two hours after desmopressin administration (p=0.000), which was maintained for up to six hours in 77% (p=0.000). In group II, 92% achieved the therapeutic value in two hours (p=0.003), which continued until six hours in 83% (p=0.000).  Conclusions:  Response to desmopressin administration was maximum at two hours, when it began to decrease progressively, but maintained the therapeutic effect. Although no adverse effects were found, there is variability of response among patients.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[enfermedad de von Willebrand]]></kwd>
<kwd lng="es"><![CDATA[hemofilia A]]></kwd>
<kwd lng="es"><![CDATA[trastornos hemorrágicos]]></kwd>
<kwd lng="es"><![CDATA[trastornos de la coagulación sanguínea]]></kwd>
<kwd lng="es"><![CDATA[desmopresina]]></kwd>
<kwd lng="en"><![CDATA[von Willebrand disease]]></kwd>
<kwd lng="en"><![CDATA[type A hemophilia]]></kwd>
<kwd lng="en"><![CDATA[hemorrhagic disorders]]></kwd>
<kwd lng="en"><![CDATA[blood coagulation disorders]]></kwd>
<kwd lng="en"><![CDATA[desmopressin]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leal]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Alberca]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Asuero]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Bóveda]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Carpio]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Contreras]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Documento "Sevilla" de Consenso sobre Alternativas a la Transfusión de Sangre Alogénica]]></article-title>
<source><![CDATA[Med Clin (Barc)]]></source>
<year>2006</year>
<volume>127</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>3-20</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Franchinia]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mannucci]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Von Willebrand factor (Vonvendi(r)) the first recombinant product licensed for the treatment of von Willebrand disease]]></article-title>
<source><![CDATA[Expert Rev Hematol]]></source>
<year>2016</year>
<volume>9</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>825-30</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Özgönenel]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Rajpurkar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lusher]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[How do you treat bleeding disorders with desmopressin]]></article-title>
<source><![CDATA[Postgrad Med J]]></source>
<year>2007</year>
<volume>83</volume>
<page-range>159-63</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stoof]]></surname>
<given-names><![CDATA[SCM]]></given-names>
</name>
<name>
<surname><![CDATA[Schütte]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Leebeek]]></surname>
<given-names><![CDATA[FWG]]></given-names>
</name>
<name>
<surname><![CDATA[Cnossen]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Kruip]]></surname>
<given-names><![CDATA[MJHA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Desmopressin in haemophilia The need for a standardised clinical response and individualised test regimen]]></article-title>
<source><![CDATA[Haemophilia]]></source>
<year>2017</year>
<volume>23</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>861-7</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iorio]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Remmington]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Jahnke]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Dwan]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Hall]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Desmopressin acetate (DDAVP) for preventing and treating bleeding in people with mild or moderate haemophilia A]]></article-title>
<source><![CDATA[Cochrane Database Systematic Reviews]]></source>
<year>2015</year>
<volume>12</volume>
<page-range>CD011985</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schütte]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[van Hest]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Stoof]]></surname>
<given-names><![CDATA[SCM]]></given-names>
</name>
<name>
<surname><![CDATA[Leebeek]]></surname>
<given-names><![CDATA[FWG]]></given-names>
</name>
<name>
<surname><![CDATA[Cnossen]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Kruip]]></surname>
<given-names><![CDATA[MJHA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacokinetic Modelling to Predict FVIII:C Response to Desmopressin and Its Reproducibility in Non severe Haemophilia A Patients]]></article-title>
<source><![CDATA[Thromb Haemost]]></source>
<year>2018</year>
<volume>118</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>621-9</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leissinger]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Carcao]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gill]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Journeycake]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Singleton]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Valentino]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Desmopressin (DDAVP) in the management of patients with congenital bleeding disorders]]></article-title>
<source><![CDATA[Haemophilia]]></source>
<year>2014</year>
<volume>20</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>158-67</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Franchini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The use of desmopressin as a hemostatic agent A concise review]]></article-title>
<source><![CDATA[Am. J. Hematol]]></source>
<year>2007</year>
<volume>82</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>731-5</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mannucci]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
</person-group>
<source><![CDATA[La desmopresina (DDAVP) en el tratamiento de los trastornos de la coagulación]]></source>
<year>2012</year>
<edition>revisada</edition>
<publisher-loc><![CDATA[Canadá ]]></publisher-loc>
<publisher-name><![CDATA[Federación Mundial de Hemofilia]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hews-Girard]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Rydz]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Goodyear]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Poon]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Desmopressin in non-severe haemophilia A Test-response and clinical outcomes in a single Canadian centre review]]></article-title>
<source><![CDATA[Haemophilia]]></source>
<year>2018</year>
<volume>24</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>720-5</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Besser]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
<name>
<surname><![CDATA[Ortmann]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Klein]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Haemostatic management of cardiac surgical haemorrhage]]></article-title>
<source><![CDATA[Anaesthesia]]></source>
<year>2015</year>
<volume>70</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>87-95</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stoof]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Cnossen]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[de Maat]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Leebeek]]></surname>
<given-names><![CDATA[FW]]></given-names>
</name>
<name>
<surname><![CDATA[Kruip]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Side effects of desmopressin in patients with bleeding disorders]]></article-title>
<source><![CDATA[Haemophilia]]></source>
<year>2016</year>
<volume>22</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>39-45</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castaman]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Tosetto]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Federici]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Rodeghiero]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance]]></article-title>
<source><![CDATA[Thromb Haemost]]></source>
<year>2011</year>
<volume>105</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>647-54</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Juul]]></surname>
<given-names><![CDATA[KV]]></given-names>
</name>
<name>
<surname><![CDATA[Klein]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
<name>
<surname><![CDATA[Sandström]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Erichsen]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Nørgaard]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gender difference in antidiuretic response to desmopressin]]></article-title>
<source><![CDATA[Am J Physiol Renal Physiol]]></source>
<year>2010</year>
<volume>300</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>F1116-22</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abed]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ainousa]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dental management of patients with inherited bleeding disorders: a multidisciplinary approach]]></article-title>
<source><![CDATA[Gen Dent.]]></source>
<year>2017</year>
<volume>65</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>56-60</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
